Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate. - Wikidata - wikimedia - TriplyDB

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

http://www.wikidata.org/entity/Q35343060

about

Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy Pharmacodynamics of piperacillin alone and in combination with tazobactam against piperacillin-resistant and -susceptible organisms in an in vitro model of infection.New advances in the use of antimicrobial agents in surgery: intra-abdominal infections.Beta-lactamase inhibitor combinations with extended-spectrum penicillins: factors influencing antibacterial activity against enterobacteriaceae and Pseudomonas aeruginosa.Relevant breakpoints for ticarcillin-clavulanic acid should be set primarily with data from ticarcillin-resistant strains.In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli.Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens.Comparison of four antimicrobial susceptibility testing methods to determine the in vitro activities of piperacillin and piperacillin-tazobactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa Current antimicrobial therapy of anaerobic infections.Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics.Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test.Antimicrobial therapy for the elderly patient.Nonfermenting Gram-negative Bacilli other than Pseudomonas aeruginosa and Acinetobacter Spp. Causing Respiratory Tract Infections in a Tertiary Care Center.Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players.Pharmacodynamics of Cefepime Combined with Tazobactam against Clinically Relevant Enterobacteriaceae in a Neutropenic Mouse Thigh Model.Kinetic interactions of tazobactam with beta-lactamases from all major structural classes.Ex vivo pharmacodynamic study of piperacillin alone and in combination with tazobactam, compared with ticarcillin plus clavulanic acid.Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children.Structural/mechanistic insights into the efficacy of non-classical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates.Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination.Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations.In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.Rational prescribing of extended-spectrum penicillin beta-lactamase inhibitor combinations: focus on ticarcillin/clavulanic acid.Piperacillin/tazobactam in the treatment of lower respiratory tract infections: an open non-comparative and multicentered trial. Latin American Clinical Research Group.Pharmacokinetics of tazobactam M1 metabolite after administration of piperacillin/tazobactam in subjects with renal impairment.An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections.Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy.Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.In vitro susceptibilities of feline and canine Escherichia coli and Pseudomonas spp. isolates to ticarcillin and ticarcillin-clavulanic acid.

P2860

Q24533461-8DA26927-205A-443B-B7C5-A8D0C273CD57 Q33751794-A1141D49-0401-41F3-B898-8AD9053927B2 Q33761118-809544DF-BC0D-4A1E-BF28-C1D3AD81BEC1 Q33840063-3372CE6E-4090-42F5-BB23-1576FD9D6A7E Q34042624-1A36F2C4-BDAE-4C1A-AA2F-68144FB99743 Q34550306-F9155519-F3C1-491D-B7EA-37B4D5A1377C Q34734070-F66FFAEA-4FB2-4ADD-B7A4-F9A356024039 Q35139002-937D9596-3BC9-46C5-9A07-10FA61823B9B Q35155857-84DE8ED3-01EF-41CB-8E23-4142DC357E3F Q35212734-6D1EA0D9-E43D-463E-BC9B-EFCA1E4D37D6 Q35650111-F52AD225-C94F-41BA-9C36-A0286D614C2F Q36531349-08ED662A-60B0-46F1-A099-D234BB35F82A Q38006505-449E7F73-AA54-4BE0-9161-15CF7B1CD168 Q38347369-C2113B5E-FB04-462D-BE73-C0E298970491 Q38650049-2FF755CE-12C2-4E6B-A8BF-ABDAC69A0A66 Q38718394-7F7AAC1D-49E2-40D2-8EF3-10C8F725E0AE Q39865634-2A5DE64E-BAB7-442D-AEFA-FA45B15EEB6D Q39866597-EC908EC1-E26B-447E-8B52-216B278A04FF Q39867395-A1C603D0-87AD-4039-BDF1-5D12C61916E6 Q40064693-E0DBBDAC-A648-433D-A625-8A36C5A72789 Q40471195-00DCE3DA-B677-4440-99C1-AF77027D345C Q40723790-1CC57686-66D0-40DB-A7EC-6FB5C65AAE42 Q41189315-52AEF549-725C-4A40-9384-ECC2591573E7 Q41220604-38CF999B-6D77-4A13-BB4A-D74CB557BC27 Q41707283-114DFF30-127F-4947-9E48-46A195A49714 Q42595403-584DE59E-4457-4904-8546-803A2C13EA3E Q49166528-0F19A677-565F-467C-9831-F0268BCD077A Q53989640-52C8081C-8083-4043-AFD8-D0D374C80942 Q54200563-29C6FEFD-EC11-4FAC-BE87-93919F59C6C7 Q54246543-27FB5201-E58F-45C7-BDDF-71177956E186 Q54312560-0ABC0C57-48F9-451E-B69F-E9C9CACD1545

P2860

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

http://www.wikidata.org/entity/Q35343060

description

1989 nî lūn-bûn

@nan

1989 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1989 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1989年の論文

@ja

1989年論文

@yue

1989年論文

@zh-hant

1989年論文

@zh-hk

1989年論文

@zh-mo

1989年論文

@zh-tw

1989年论文

@wuu

name

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

@ast

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

@en

type

label

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

@ast

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

@en

prefLabel

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

@ast

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

@en

P1433

Q35343060-351E35E5-69BD-4E99-A84E-F203058EADBF

P1476

Q35343060-C3D82086-7E7F-49FE-851B-7A2F5C26AC1A

P2093

Q35343060-1ED611FE-3FF7-4755-834B-D4D1396EB37E

Q35343060-3D4AA1E2-56AC-4433-A5DE-0FCF85D6CAD1

P2860

Q35343060-32D928BC-6931-4318-BE6A-2540CD17A499

Q35343060-349A0343-384E-4ABF-8EF9-A031A3894031

Q35343060-7C740789-B72F-4E1B-9E7C-64CE5A96C642

Q35343060-8C6CD700-8FA4-4C99-91C2-969468D938BD

Q35343060-D7A7FAD6-7B62-45A3-A2EF-5684B4432285

Q35343060-D81464E6-1ED1-47EC-921F-E0987BD35F7E

Q35343060-EF513DDD-64DF-4F1C-8544-A60D13A883EF

P304

Q35343060-7070DF55-029A-49B5-9F22-119970E07E93

P31

Q35343060-E581688B-55CD-4695-8A25-63CC60D0334F

P356

Q35343060-EA99EADE-EEF3-4556-B104-AFC546B40DFE

P407

Q35343060-4A7366FB-1839-4A6C-A869-62422A8F6B9E

P433

Q35343060-FA20A5EA-B04C-4F4F-8BD2-48952E63930F

P478

Q35343060-CDA7A4E4-528C-4896-A048-619E115EA2C8

P577

Q35343060-358C0985-1B0D-4D5F-A5A2-8CC15FD61A54

P698

Q35343060-E8C70D83-55C6-4B31-9788-8C35EAE9EC30

P932

Q35343060-29D83048-2F55-4CB2-8560-977F1E373188

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate.

@en

P2093

Fass RJ

http://www.w3.org/2001/XMLSchema#string

Prior RB

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin

National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae

Resistance to ticarcillin-potassium clavulanate among clinical isolates of the family Enterobacteriaceae: role of PSE-1 beta-lactamase and high levels of TEM-1 and SHV-1 and problems with false susceptibility in disk diffusion tests.

In vitro susceptibilities of four species of coagulase-negative staphylococci.

Comparative activity of beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with beta-lactams against beta-lactamase-producing anaerobes

Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.

Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases.

P304

1268-1274

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.33.8.1268

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P577

1989-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

2552904

http://www.w3.org/2001/XMLSchema#string

P932

172638

http://www.w3.org/2001/XMLSchema#string